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Studies reported a strong genetic correlation between the Big Five personality traits 
and major depressive disorder (MDD). Moreover, personality traits are thought to be 
associated with response to antidepressants treatment that might partly be mediated by 
genetic factors. In this study, we examined whether polygenic scores (PGSs) derived from 
the Big Five personality traits predict treatment response and remission in patients with 
MDD who were prescribed selective serotonin reuptake inhibitors (SSRIs). In addition, 
we performed meta-analyses of genome-wide association studies (GWASs) on these 
traits to identify genetic variants underpinning the cross-trait polygenic association. The 
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PGS analysis was performed using data from two cohorts: the Pharmacogenomics 
Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS, 
n = 529) and the International SSRI Pharmacogenomics Consortium (ISPC, n = 865). 
The cross-trait GWAS meta-analyses were conducted by combining GWAS summary 
statistics on SSRIs treatment outcome and on the personality traits. The results showed 
that the PGS for openness and neuroticism were associated with SSRIs treatment 
outcomes at p < 0.05 across PT thresholds in both cohorts. A signiﬁcant association 
was also found between the PGS for conscientiousness and SSRIs treatment response 
in the PGRN-AMPS sample. In the cross-trait GWAS meta-analyses, we identiﬁed eight 
loci associated with (a) SSRIs response and conscientiousness near YEATS4 gene and 
(b) SSRI remission and neuroticism eight loci near PRAG1, MSRA, XKR6, ELAVL2, 
PLXNC1, PLEKHM1, and BRUNOL4 genes. An assessment of a polygenic load for 
personality traits may assist in conjunction with clinical data to predict whether MDD 
patients might respond favorably to SSRIs.
Keywords: pharmacogenomics, polygenic score, personality traits, major depression, antidepressants, selective 
serotonin reuptake inhibitors
INTRODUCTION
A major depressive disorder (MDD) is the most common and 
disabling mental health diseases worldwide (1, 2) with a lifetime 
prevalence of ~12% (3). Studies estimated a 61.6 million years 
of life lived with disability caused by MDD accounting for 2.5% 
of the total disability-adjusted life years and for 8.1% of the total 
years lived with disability resulted from all diseases (2, 4).
Selective serotonin reuptake inhibitors (SSRIs) are commonly 
used as the first-line pharmacological treatment for MDD (5). 
However, treatment efficacy with SSRIs varies widely between 
individual patients and is inadequate in many cases. Clinical 
response rates range from 48 to 64% (6, 7) and reported remis-
sion rates are as low as 23.5% (7, 8). To improve this situation, an 
investigation of the biological and psychosocial factors that drive 
heterogeneity in treatment outcomes is necessary.
There is growing evidence from genetic studies that antide-
pressant treatment response is substantially influenced by genes 
(7, 9–17). A study involving nearly 3,000 MDD patients estimated 
that genetic factors explain 42% of the differences in the level of 
treatment response (18). A number of genes and single nucleotide 
polymorphisms (SNPs) that could influence antidepressant treat-
ment outcomes have been reported, including polymorphisms 
within the COMT (9), HTR2A (10), HTR1A (11), CNR1 (11), 
SLC6A4 (12), NPY (13), MAOA (14), and IL1B (15) genes. A 
pharmacogenomic study on SSRIs response by the International 
SSRIs Pharmacogenomics Consortium (ISPC) identified several 
SNPs with suggestive association after 4  weeks of treatment, 
including the neuregulin-1 gene, which is involved in many 
aspects of brain development, such as neuronal maturation (7).
In addition to genetic factors, multiple demographic, 
clinical, and psychological predictors of SSRI response in 
MDD have been identified, collectively explaining 5–15% 
of the variance in treatment outcomes (19–23). Among the 
psychological predictors, personality traits defined by the 
Five-Factor Model of Personality (“Big Five”: extraversion, 
agreeableness, conscientiousness, neuroticism, openness) (24) 
have previously been reported to influence antidepressant 
treatment response and remission (25–29). Of these, neuroti-
cism is a frequently reported predisposing factor for depression 
and was shown to negatively affect antidepressants treatment 
response (30, 31). In a recent study, MDD patients resistant to 
antidepressants were more likely to report high clinical scores 
for neuroticism, but low scores for openness, conscientious-
ness, and extraversion (26). In a large study of patients with 
MDD (n  =  8,229), pre-existing personality dysfunction was 
associated with poor response to antidepressants (27). Further, 
some studies have suggested that SSRIs have a direct positive 
impact on scores for neuroticism or extraversion in MDD 
patients, and that part of the antidepressant effect might be 
explained through these adjustments (28, 29, 32, 33). Moreover, 
shared genes are thought to play a key role in the association 
between personality factors and MDD (34). For example, stud-
ies have estimated the genetic correlation between MDD and 
neuroticism at 55–75% (35, 36). However, no previous work 
has directly addressed the question whether there is a genetic 
relationship between the Big Five personality traits and SSRI 
treatment response and remission in MDD. It has been shown 
that the genetic architecture of personality traits is highly 
polygenic, in which several genes of small effect contribute to 
the overall phenotype (35, 37). Thus, a polygenic score (PGS) 
analysis approach proposed by the schizophrenia consortium 
(38) and later applied in several studies (16, 39), is potentially 
powerful to investigate the genetic influence of each of the Big 
Five personality traits on antidepressant treatment outcomes. 
A PGS for each of the Big five personality traits quantifies the 
combined effects of genetic variants across the whole genome, 
computed as a weighted summation of effect sizes obtained 
from genome-wide association studies (GWASs). A successful 
multi-trait polygenic model may assist for an early screening of 
diseases risk, clinical diagnosis, and the prediction of treatment 
response and prognosis (38, 39).
TABLE 1 | Baseline characteristics of major depressive disorder patients and 








Responders, N (%) 206 (44.4) 416 (48.1) 622 (46.8)
Remitters, N (%) 128 (27.6) 226 (26.1) 354 (26.7)
Age, mean (SD) 39.6 (13.7) 43.7 (14.7) 42.2 (14.5)
Sex, female, N (%) 335 (63.3) 561 (64.9) 896 (64.3)
PGRN-AMPS, the Pharmacogenomics Research Network Antidepressant Medication 
Pharmacogenomics Study; ISPC, the International SSRI Pharmacogenomics 
Consortium study.
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Implicitly, one could also interpret a polygenic association as 
a biological relationship partly explained by the role of shared 
genes and common molecular mechanisms. With this in mind, 
we conducted GWAS meta-analyses by combining GWAS sum-
mary statistics on the Big Five personality traits and SSRIs treat-
ment outcome to identify shared genes involved in the cross-trait 
association.
MATERIALS AND METHODS
The characteristics of the clinical and genetic data, as well as the 
sources of the GWAS summary statistics used in our analysis are 
described below.
Study Samples
Pharmacogenomics Research Network 
Antidepressant Medication Pharmacogenomic Study 
(PGRN-AMPS)
The PGRN-AMPS is a clinical trial on the response to escit-
alopram or citalopram of 529 MDD patients over 8  weeks of 
treatment. The baseline and follow-up assessment of depression 
severity were performed using the 16-item Quick Inventory of 
Depressive Symptomatology (QIDS-C16) (40).
ISPC Study
The ISPC is an International Consortium established to discover 
genes that are responsible for SSRIs treatment response in patients 
with MDD. For our study, we used data from 865 MDD patients 
recruited in the USA, Germany, Thailand, Taiwan, and Japan 
who received SSRI treatment. The 17-item Hamilton Depression 
Rating Scale was used as a measurement tool to assess and follow-
up the treatment progress (7).
Genotyping and Quality Control
The genotype and clinical data for the PGRN-AMPS were avail-
able via a controlled access system at the database of Genotypes 
and Phenotypes: dbGaP1 and the ISPC data were obtained from 
the ISPC consortium (7).
For the genotype data of both samples, we implemented qual-
ity control (QC) steps using PLINK (41) and samples with low 
genotype rates <95%, sex inconsistencies (X-chromosome het-
erozygosity), and genetically related individuals were excluded. 
We also excluded SNPs that had poor genotyping rate <95%, 
an ambiguity (A/T and C/G SNPs), a minor allele frequency 
(MAF  ≤  1%), or showed deviation from Hardy–Weinberg 
Equilibrium (p < 10–6).
Imputations
Genotype data passing QC criteria were imputed in the Michigan 
server2 (42), separately for each study samples using 1000 
Genomes project reference panel.
After excluding the low-frequency SNPs (MAF  <  10%), 
poor-quality variants (imputation INFO <0.9 and indels), the 
imputed dosages were converted to best guess genotypes. The 
1 http://www.ncbi.nlm.nih.gov/gap.
2 https://imputationserver.sph.umich.edu
subsequent PGS analyses were performed using the best guess 
genotypes.
GWAS Summary Statistics Data
The PGSs were calculated using the approach previously described 
by the International Schizophrenia Consortium (38). This 
method requires an estimated effect size for each SNP to compute 
weighted PGS. The effect estimates (betas) for this study were the 
summary statistics obtained from previously published GWASs 
on extraversion, openness, agreeableness, conscientiousness (37), 
and on neuroticism (35). The data were publicly available for 
download at http://www.tweelingenregister.org/GPC/ and http://
www.thessgac.org/data, respectively. The effect size estimates for 
each SNP—quantified as beta was extracted from the download 
file and used to compute weighted PGS in the PGRN-AMPS and 
ISPC cohorts.
Deﬁnition of SSRI Treatment Outcomes
Treatment response and remission to SSRIs were defined after 
4 weeks of treatment follow-up of MDD patients in both cohorts. 
In addition, PGS associations were evaluated at 8  weeks in 
PGRN-AMPS. While treatment response was determined as a 
≥50% reduction from baseline in the HRSD-17 or QIDS-C16 
total scores, SSRI treatment remission was defined as achieving 
a HRSD-17 score ≤7 or a QIDS-C16 score d5 at 4 or 8 weeks of 
treatment.
Data on the covariates—age, gender, and type of SSRIs medi-
cations were also collected and the details can be found in earlier 
publications (7, 40, 43).
Statistical Analyses
PGS Computation and Association Analyses
The PGSs were computed for each of the Big Five personality 
traits using imputed genetic data weighted by GWAS summary 
statistics of the respective personality traits, separately for 
the two cohorts: PGRN-AMPS (n = 529) and ISPC (n = 865) 
(Table 1; Figure 1). First, quality-controlled SNPs were clumped 
for linkage disequilibrium (LD) using genome-wide association 
p-value informed clumping with r2 = 0.1 in a 250-kb window to 
create an independent SNP-set using PLINK software run on 
Linux. Next, weighted PGSs were calculated for each individual 
at a range of p-value thresholds (PT) as a weighted sum of allele 
dosages (0, 1, or 2). The PT refers to the p-values associated 
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with the effect size of each of the SNPs, as listed in the GWAS 
summary statistics (35, 37). The weighting was performed by 
multiplying the dosage of each effect increasing allele by its effect 
size derived from the GWAS summary statistics (β-coefficient), 
then divided by the total number of SNPs in each threshold. The 
PGS was computed at a range of PT (<1 × 10–2, <5 × 10–2, <0.1, 
<0.2, <0.3, <0.4, <0.5, and <1.0) separately for each of the two 
cohorts. Performing the PGS at different PT provides a range 
of alternative scores to choose the most significantly associated 
(optimal) PGS that will be used for prediction modeling. At 
each PT, a logistic regression modeling was applied to response/
remission to SSRIs (dependent variables) using the PGS for each 
of the Big Five personality traits as the main predictor variable 
and adjusting for common covariates, such as age, sex, and 
cohort-specific covariates including four principal components 
in the PGRN-AMPS and “study sites” in the ISPC. A statistically 
significant association between the PGSs for the Big Five per-
sonality traits and response/remission to SSRIs was determined 
at p < 0.05, across the PT in both study samples. The prediction 
accuracy, the percentage of variance explained, Nagelkerke R2, 
by the PGSs were calculated as the Nagelkerke R2 of the full 
model with PGS and covariates minus the Nagelkerke R2 of the 
model with only covariates. To determine the effect of high or 
low polygenic load on treatment outcomes, the study subjects 
were grouped into PGS quartiles (Q1–Q4) at the optimal PT. 
Then, we estimated the odds of treatment response/remission to 
SSRIs for MDD patients within the group with a high polygenic 
load for the Big Five personality traits (Q2, Q3, Q4) compared to 
patients in the lowest PGS quartile (Q1).
Cross-Trait Meta-Analyses of GWASs
In the cross-trait meta-analyses, we applied the O’Brien’s (OB) 
method and the direct Linear Combination of dependent test 
statistics (dLC) approach (39, 44, 45), which are implemented 
in the C++ eLX package. Briefly, the OB method and the dLC 
approach help to combine GWAS effect estimates of genome-
wide SNPs, obtained from univariate GWASs and generated two 
test statistics and associated p-values—one for the OB method 
and one for the dLC method. More details can be found elsewhere 
(44, 45). The eLX package is available at https://sites.google.com/
site/multivariateyihsianghsu/.
Here, GWAS on personality traits that have shown a signifi-
cant association in the PGS analysis were combined with GWAS 
on SSRIs treatment outcome. The GWAS summary statistics 
on SSRIs treatment response (7) were combined with those on 
(i) conscientiousness (34) and (ii) openness personality (34). 
Similarly, the GWAS summary statistics on SSRIs treatment 
remission (7) was meta-analyzed with (i) openness personality 
(34) and (ii) neuroticism (35).
Statistical significance was determined based on the smaller of 
the OB or the dLC p-values. A significant association was deter-
mined if (1) the p-value for the cross-trait meta-analysis reached 
genome-wide significance (p < 5 × 10−8) and (2) the univariate 
GWAS effects were at least nominally significant (p < 0.05). For 
each cross-trait meta-analysis, only one lead SNP per locus was 
reported. Nearby SNPs in LD (r2 > 0.1) with the lead SNP were 
considered dependent and belonging to the same locus.
RESULTS
Patient Characteristics and Treatment 
Outcomes
In this study, we analyzed data from 1,394 MDD patients who had 
SSRI treatment divided into PGRN-AMPS (n = 529) and ISPC 
(n = 865) samples. The average age of the patients was 42.2 years 
and the majority of them (64.3%) were females (Table 1).
Of all patients, 622 (46.8%) were classified as treatment 
responders with a slight variation across the study samples 44.4% 
in the PGRN-AMPS and 48.1% in the ISPC. Remission rates were 
27.6 and 26.1% in the PGRN-AMPS and ISPC samples, respec-
tively. The rate of remission combined across the two studies was 
26.7% (Table 1).
Association of the PGS for the Big Five 
Personality Traits with SSRIs Treatment 
Outcomes
Polygenic scores were computed for each of the Big Five person-
ality traits, and we investigated their association with two SSRI 
treatment outcomes—response and remission, after 4  weeks 
(PGRN-AMPS and ISPC) and 8  weeks (PGRN-AMPS) of 
treatment.
After 4 weeks of treatment, genetic predisposition to openness, 
conscientiousness, and neuroticism were associated with SSRIs 
treatment response and/or remission at p < 0.05 across PT thresh-
olds, in at least one of the two assessed cohorts (Figures 1A–C). 
Genetic loading for openness was associated with response and 
remission in both cohorts (Figure 1A1,2). An elevated PGS for 
conscientiousness was associated with treatment response, but 
not remission, in the PGRN-AMPS sample only (Figure 1B). A 
PGS association for neuroticism with remission, but not treat-
ment response, was shown in both cohorts (Figure 1C). The PGSs 
for extraversion and agreeableness were associated with neither 
response nor remission.
We also assessed the level of observed variation in SSRI 
treatment outcomes accounted for by these personality traits, 
and found that personality traits at the most significant thresh-
olds explained a considerable amount of variance in treatment 
outcomes. For example, the PGS for openness accounted for 
~1.5% of the observed variation in SSRIs treatment response 
and ~2.8% of the variance in remission. The PGS for neuroticism 
explained ~1.5% of the variance in remission and the PGS for 
conscientiousness contributed to ~1.5% of the variability in SSRI 
treatment response.
The status of treatment response and remission for patients 
in personality trait quartiles (Q2–Q4) was compared with those 
in the lowest personality trait PGS quartile (Q1) (Figure  2). 
Our analysis revealed that MDD patients with a high polygenic 
load for openness personality had initially poorer remission and 
response rates at 4 weeks of treatment, with Q4 versus Q1 odds 
ratios (ORs) ranging from 0.30 [ISPC: 95%CI, 0.15–0.59] to 0.52 
[PGRN-AMPS: 95%CI, 0.29–0.90] (Figure  2A1,2, green and 
brown graphs). After longer treatment duration, we observed a 
reverse effect. Here, a higher polygenic load for openness was 
associated with a better SSRIs treatment response at 8  weeks 
FIGURE 1 | The bar graphs (A–C) show the association of the PGSs for the Big Five personality traits with SSRIs response or remission at different p-value 
thresholds (PT) after 4 weeks of treatment in the PGRN-AMPS (n = 529) and ISPC (n = 865) samples. The y-axis (Nagelkerke’s Pseudo-R2) refers to the percentage 
of variance in SSRIs treatment response/remission accounted for the PGSs of the Big Five personality traits at a particular PT in each sample. On the x-axis, plotted 
from left to right, are the GWAS PT for personality traits used to group the SNPs for the PGSs. The *sign on the top of each bar signify the statistical signiﬁcance of 
the PGS association as *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: PGRN-AMPS, the Pharmacogenomics Research Network Antidepressant Medication 
Pharmacogenomic Study; ISPC, the International SSRI Pharmacogenomics Consortium study; SNP, single nucleotide polymorphism; PGS, polygenic score; SSRIs, 
selective serotonin reuptake inhibitors.
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in the PGRN-AMPS, with OR of 1.58 [95%CI, 1.10–2.90] 
(Figure 2A1,2, blue graphs).
Major depressive disorder patients with a higher polygenic load 
for conscientiousness personality had 1.95 [95% CI, 1.13–3.36] 
times better SSRIs treatment response compared to those patients 
in the lowest PGS, although this association was only significant 
in the PGRN-AMPS sample at 4 weeks of treatment (Figure 2B).
Conversely, MDD patients with a higher polygenic load for 
neuroticism personality had poorer treatment outcomes with 
SSRIs. After 4 weeks of treatment, patients in Q4 based on the 
PGS for neurotic personality had about 50% lower odds of 
remission compared to patients in Q1 with OR ranging from 
0.50 [PGRN-AMPS: 95%CI, 0.28–0.90] to 0.54 [ISPC: 95%CI, 
0.33–0.89] (Figure 2C). Constantly, results after 8 weeks of treat-
ment showed a trend inverse association between the PGS for 
neurotic personality and SSRIs treatment remission, although 
this was not statistically significant (Figure 2C).
To assess the potential effect of false-positive findings, the 
association p-values were corrected for multiple testing at each PT 
for SSRIs treatment response and remission using the Benjamini 
and Hochberg (BH) method. Each of the p-values was adjusted 
assuming a conventionally accepted level of 5% false discovery 
rate (FDR) (46). After FDR adjustment, the associations of the 
PGS for openness personality with SSRIs treatment response 
remained statistically significant (in the ISPC sample: FDR 
adjusted p-value  =  0.02 at PT  <  1  ×  10−2) and with remission 
(in the PGRN-AMPS sample: FDR adjusted p-value  =  0.04 at 
PT < 5 × 10−2). The PGSs for conscientiousness and neuroticism 
were not associated with SSRIs treatment outcome after imple-
menting the FDR adjusted p-value <0.05.
Cross-Trait Meta-Analyses of GWASs
For personality traits that showed a significantly associated PGS, 
cross-trait GWAS meta-analyses was performed by combining 
summary GWAS data on SSRIs treatment outcomes and per-
sonality traits. Table 2 and Figure 3 summarize the cross-trait 
meta-analyses findings, including the list of genetic loci and 
nearest genes that are potentially overlapping between the traits. 
At a p-value of <5 × 10−8, we identified eight genetic loci located 
within or near to protein-coding genes with possible overlapping 
effects on SSRIs treatment outcomes and personality traits. We 
found (i) one locus associated with conscientiousness and SSRI 
response near the YEATS4 gene (Table  2; Figure  3A) and (ii) 
seven loci associated with remission and neuroticism located at 
FIGURE 2 | The line plots represent the ORs for favorable response or remission to selective serotonin reuptake inhibitors treatment in patients with MDD with a 
high personality traits polygenic load (Q2, Q3, and Q4) compared to patients with the lowest polygenic load (Q1), estimated at the most signiﬁcant p-value 
thresholds. The quartile-based polygenic scores analyses were performed using data at 4 weeks in the ISPC and at 4 and 8 weeks in the PGRN-AMPS. A polygenic 
loading for openness personality trait was initially associated with poor response and remission to selective serotonin reuptake inhibitors (SSRIs) in the ﬁrst 4 weeks 
of treatment (ISPC, PGRN-AMPS at 4 weeks). After a longer (8 weeks) treatment follow-up, the genetic loading for openness had shown a favorable effect to SSRIs 
response and remission (PGRN-AMPS at 8 weeks). The polygenic loading for conscientiousness personality was favorably associated with response to SSRIs 
treatment. However, a polygenic loading for neuroticism personality had shown a negative impact on SSRIs remission. The ORs are reported on the lines and the 
*sign indicates the statistical signiﬁcance of the ORs as *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: PGRN-AMPS, the Pharmacogenomics Research 
Network Antidepressant Medication Pharmacogenomic Study; ISPC, the International SSRI Pharmacogenomics Consortium study. OR, odds ratio; Q1, quartiles 1; 
Q2, quartiles 2; Q3, quartiles 3; Q4, quartiles 4; MDD, major depressive disorder.
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or near PRAG1, MSRA, XKR6, ELAVL2, PLXNC1, PLEKHM1, 
and BRUNOL4 genes (Table  2; Figure  3B). From the meta-
analyses of SSRIs treatment outcomes with openness personality, 
we identified only suggestive evidence at significance p < 1 × 10−6 
(Table 2).
DISCUSSION
In this study, we analyzed data from 1,394 MDD patients who 
had been treated with SSRIs and assessed whether it is possible 
to predict antidepressants treatment outcomes—response and 
remission, using PGS for the Big Five personality traits. To fur-
ther validate the PGS association findings and provide additional 
evidence, cross-trait meta-analyses of GWASs on SSRIs treatment 
outcomes versus GWASs on the Big Five personality traits were 
performed. Our findings from both analyses found complemen-
tary evidence that the association of the Big Five personality traits 
with SSRIs treatment outcomes is partly genetic.
Among the Big Five personality traits, the PGS for openness, 
conscientiousness, and neuroticism were significantly associated 
with SSRI treatment outcomes in patients with MDD. A high 
polygenic load for openness predicted poorer odds of response 
and remission to SSRIs after 4  weeks of treatment. However, 
after 8 weeks of treatment, the odds of response and remission 
was reversed and high loading for openness was associated with 
favorable outcomes. Patients with a high polygenic load for 
conscientiousness had a better odd of response to SSRIs after 
4  weeks of treatment, but were neither more nor less likely to 
have good outcomes after 8  weeks. In contrast, patients who 
possessed a higher polygenic load for neuroticism risk genetic 
variants responded poorer to SSRIs treatment at both time points.
The discrepancy between short-term and intermediate-term 
treatment outcomes in patients with high polygenic loading for 
openness was unexpected in the context of the previous litera-
ture (26, 27), and raises the question whether statements about 
personality impact on SSRI treatment outcomes can be reliably 
reached on the basis of assessments conducted within the first 
month. While longitudinal studies of treatment outcomes in 
MDD suggest that treatment response within the first month 
occurs for a majority of patients who will eventually remit (47), 
TABLE 2 | Signiﬁcant loci resulting from the cross-trait meta-analyses of genome-wide association studies (GWASs) on selective serotonin reuptake inhibitors (SSRIs) 
treatment response/remission and GWAS on the Big Five personality traits at univariate GWAS p-value <5 × 10−2 and Cross-trait meta-analysis p-value <5 × 10−8.
SNP Chr Position 
Ch37










rs7555693 1 106838539 A G 6.46 × 10−3 4.485 × 10−5 1.37 × 10−6 PRMT6 −−
rs9321987 6 145030284 A G 7.49 × 10−3 1.056 × 10−5 5.05 × 10−7 UTRN −−
rs352759 8 15599714 T A 6.16 × 10−4 2.820 × 10−4 5.52 × 10−7 TUSC3 +−
rs7828021 8 50640014 C G 3.68 × 10−3 2.913 × 10−6 7.43 × 10−8 SNTG1 −−
rs11591827 10 82887882 A G 1.87 × 10−2 4.643 × 10−6 8.70 × 10−7 SH2D4B −−
rs7189979 16 12630187 C A 2.28 × 10−3 1.659 × 10−5 1.77 × 10−7 SNX29 +−
SSRIs response (N = 865) (7) Conscientiousness (N = 260,861) (34)
rs3825243 12 69750839 A G 5.78 × 10−4 1.41 × 10−5 4.04 × 10−8 YEATS4 −−
SSRIs remission (N = 865) (7) Neuroticism (N = 170,911) (35)
rs2979204 8 8298857 T C 3.24 × 10−3 5.48 × 10−10 8 × 10−11 PRAG1 ++
rs11990063 8 10165195 T C 4.00 × 10−2 6.77 × 10−9 9 × 10−9 MSRA −−
rs35792458 8 10822431 C G 1.00 × 10−2 5.25 × 10−10 1 × 10−12 XKR6 −+
rs12555870 9 23347724 G A 4.00 × 10−2 1.25 × 10−6 1 × 10−8 ELAVL2 +−
rs4761545 12 94426468 G T 2.00 × 10−2 3.54 × 10−7 8 × 10−10 PLXNC1 ++
rs144733372 17 43564222 G T 1.00 × 10−2 1.23 × 10−9 3 × 10−11 PLEKHM1 −+
rs11082011 18 35145122 C T 1.00 × 10−2 8.60 × 10−9 4 × 10−8 BRUNOL4 −+
SSRIs remission (N = 865) (7) Openness (N = 260,861) (34)
rs55679149 1 89534338 T C 2.77 × 10−3 6.31 × 10−5 8.25 × 10−7 GBP1 +−
rs11728985 4 130036435 T C 1.93 × 10−2 1.24 × 10−6 4.03 × 10−7 C4orf33 −+
rs11155372 6 145019738 T G 5.11 × 10−4 5.85 × 10−5 1.28 × 10−7 UTRN −+
rs7828021 8 50640014 C G 1.23 × 10−2 2.91 × 10−6 4.18 × 10−7 SNTG1 −−
rs1411216 9 24520194 A G 7.81 × 10−3 6.88 × 10−6 4.53 × 10−7 CRIPAK ++
rs7189979 16 12630187 C A 2.82 × 10−3 1.66 × 10−5 2.73 × 10−7 SNX29 +−
A1, effect allele; A2, another allele; SNP, single nucleotide polymorphism.
The effect direction represents the SNPs effect on SSRIs treatment response or remission for the effect allele based on the ISPC GWAS (7) versus its effect on the GWASs of 
personality traits as listed in the table.
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they also indicate that there is a considerable proportion of 
patients who achieve response and remission after much longer 
treatment periods (48, 49). In this context, our finding raises the 
possibility that the different Big Five personality traits could have 
differential effects on early- versus delayed responses to treatment 
in MDD.
Moreover, the inconsistences in the direction of the relationship 
between the Big Five personality traits and response to long-term 
versus short-term treatment to SSRIs might be explained by a 
psychological theory (50–52). Studies suggested that antidepres-
sants have a primary effect on emotional processing, providing 
a platform for long-term cognitive and psychological recovery 
(50), and the clinical effects of antidepressant treatment may be 
mediated by early changes in emotional processing (51, 52).
In our data, consistency between the outcome parameters—
treatment response and remission was variable. Only the PGS for 
openness showed a significant association with both treatment 
response and remission. The PGS for conscientiousness was 
associated with better treatment response, but not with remis-
sion. The PGS for neuroticism predicted lower odds of treatment 
remission, but not poorer treatment response. At face value, these 
findings suggest that openness and neuroticism could play more 
important roles in predicting ultimate remission from depressive 
episodes, whereas conscientiousness might drive early treatment 
effects rather than longer term outcomes. However, another 
explanation is that our cohorts might have been underpowered 
to detect more consistent effects, or that some of the observed 
associations were chance findings, perhaps driven by multiple 
testing. Indeed, only the associations of the PGS for openness 
personality with SSRIs treatment response remained statistically 
significant after FDR adjustment. Therefore, future genetic stud-
ies with higher patients’ numbers are required to confirm our 
findings.
In all, our genetic findings are in line with previous clinical 
investigations of the influence of personality characteristics on 
antidepressant treatment response in MDD. A study in Japan 
revealed as depressed patients who were resistant to treatment 
had a higher neuroticism score and lower scores for openness, 
conscientiousness, and extraversion than patients who remit-
ted and healthy controls (26). In another study, higher clinical 
scores for openness at baseline were associated with improved 
treatment response to antidepressants, whereas a higher score for 
neuroticism was associated with poor treatment outcomes (53). 
More generally, poor treatment response was associated with per-
sonality dysfunction in a large sample study of more than 8,000 
antidepressant-treated adults with MDD (27). Similarly, a meta-
analysis of 34 clinical studies concluded that MDD patients with 
a comorbid personality disorder had double the risk of overall 
poor clinical and treatment outcomes, compared to patients no 
co-occurring personality disorder (54).
Additionally, previous studies have shown genetic correlations 
between Big Five personality traits and psychiatric disorders and 
FIGURE 3 | The Manhattan plots show the results of the cross-trait meta-analysis of genome-wide association studies (GWASs) on selective serotonin reuptake 
inhibitors treatment outcomes (response or remission) with GWASs on: (A) conscientiousness personality trait; (B) neuroticism personality, highlighting the loci that 
showed genome-wide signiﬁcance (orange), and the nearest genes. The −log10 (cross-trait p-value) is plotted against the physical position of each SNP on each 
chromosome. The threshold for genome-wide signiﬁcance (cross-trait p-value <5 × 10−8) is indicated by the red dotted horizontal line.
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the PGS for neuroticism was significantly associated with MDD 
(55).
Since the PGS association reflects a shared genetic etiology, 
we applied cross-trait GWAS meta-analyses by combining 
summary statistics on SSRI treatment outcomes with person-
ality traits, and identified eight overlapping genetic loci. The 
YEATS4 gene locus was associated with treatment response 
to SSRIs and conscientiousness. Previously, a gene expression 
analysis in depressed patients further replicated in mice found 
lower levels of YEATS4 in depressed patients compared to 
healthy controls. Moreover, the expression level of this gene 
was correlated with the dose of imipramine (a tricyclic anti-
depressant) (56).
The second gene locus (rs144733372) in PLEKHM, which 
was found in the cross-trait meta-analysis of neuroticism and 
SSRIs treatment remission, is highly linked (LD: r2 > 0.8) with 
several other SNPs located within the CRHR1 gene. The CRHR1 
gene encodes a G-protein coupled receptor that binds with the 
neuropeptides of the corticotrophin-releasing hormone family, 
a major regulator of the hypothalamic–pituitary–adrenal path-
way (57). Functional gene polymorphisms in the CRHR1 gene 
have been associated with SSRIs treatment response (58), and 
it moderates the association of maltreatment with neuroticism 
(59). Corticotrophin-releasing hormone signaling has previously 
been implicated in mood disorders and treatment response to 
antidepressants (60).
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Another gene showing shared associations with SSRI 
treatment response and neurotic personality is MSRA, which 
has shown the highest levels of expression in brain tissue 
(61). Previous studies reported that genetic variants within 
the MSRA gene could be associated with schizophrenia, 
bipolar disorder (62, 63), executive cognitive function (64), 
fluid intelligence (63), and self-reported irritable tempera-
ment (65).
Further, loci within the PRAG1 and PLXNC1 genes have 
shown overlapping influence on SSRI treatment and neuroticism 
personality. A genetic polymorphism rs706895C/T within the 
FYN gene belonging to the same family of genes (tyrosine protein 
kinase family) was significantly associated with personality traits 
(66). SNPs within the plexin family gene PLXNA2 have previously 
been implicated in neuroticism, depression, and psychological 
distress (67).
Overall, these findings lend further weight to our PGS analy-
ses and reinforce the idea that certain gene polymorphisms have 
a dual impact on personality structure and antidepressant treat-
ment outcomes in MDD. Studying the individual mechanism of 
each significant genetic locus in relation to antidepressants in 
the future studies might lead to novel insights in the molecular 
underpinnings of these drugs. In conclusion, our study pro-
vides evidence in the potential ability of the PGS for the Big Five 
personality traits to elucidate shared biological mechanisms 
and to predict SSRI treatment outcomes. Whether these PGSs 
could be applied to everyday clinical practice in the future 
relies on their ability to stratify MDD patients into categories 
of good treatment responders versus nonresponders. Further 
research is required to determine if this is the case. However, 
the small effect sizes found in our study give rise to cautious 
interpretation. In our view, their full clinical value likely lies in 
their contribution to multi-variable models that also comprise 
clinical and environmental factors influencing medication 
response.
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